Pritelivir-mesylate-AIC316-mesylate-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEPritelivirmesylateCat.No.:HY-15303ACASNo.:1428333-96-3Synonyms:AIC316mesylate;BAY57-1293mesylate分?式:C??H??N?O?S?分?量:498.6作?靶點(diǎn):HSV作?通路:Anti-infection儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:83.33mg/mL(167.13mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.0056mL10.0281mL20.0562mL5mM0.4011mL2.0056mL4.0112mL10mM0.2006mL1.0028mL2.0056mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請?jiān)?個?內(nèi)使?，-20°C儲存時，請?jiān)?個?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.08mg/mL(4.17mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(4.17mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(4.17mM);ClearsolutionBIOLOGICALACTIVITY?物活性Pritelivirmesylate(BAY57-1293mesylate)?種病毒解旋酶-引物酶復(fù)合物(helicase-primasecomplex)抑制劑，在體外和單純疹病毒(HSV)感染的動物模型中均具有抗病毒活性。Pritelivirmesylate對1型和2型單純疹病毒(HSV-1和HSV-2)具有活性，對HSV1-2的IC50為0.02μM[1]。IC50&TargetHSV-1HSV-20.02μM(IC50)0.02μM(IC50)體內(nèi)研究PriteliviristhefirstinaclassofantiviralagentsthatinhibitHSVreplicationbytargetingtheviralhelicase–primaseenzymecomplex[2].Pritelivir(0.03-45mg/kg)significantlyincreasessurvival.Pritelivir(0.3-30mg/kg)reducesmortalityagainstHSV-1,E-377.Pritelivirhaspotentandresistance-breakingantiviralefficacywithpotentialforthetreatmentofpotentiallylife-threateningHSVtype1and2infections,includingherpessimplexencephalitis[3].CombinationtherapiesofPritelivirat0.1or0.3mg/kg/dosewithAcyclovir(10mg/kg/dose)areprotectivewhencomparedtothevehicletreatedgroupagainstHSV-2,strainMS[3].AnimalModel:FemaleBALB/cmice[3]Dosage:0.03to45mg/kgAdministration:Administeredorally,twicedailyatapproximately12hintervals,for7daysResult:Survivalwassignificantlyincreasedto80-100%ascomparedtothevehicletreatment.Eventhelowestdoseof0.3mg/kgwaseffectiveinincreasingsurvivalto53%.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?AntivirRes.2020Nov;183:104931.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].LigatG,etal.IdentificationofAminoAcidsEssentialforViralReplicationintheHCMVHelicase-PrimaseComplex.FrontMicrobiol.2018Oct23;9:2483.[2].WaldA,etal.Helicase-primaseinhibitorPritelivirforHSV-2infection.NEnglJMed.2014Jan16;370(3):201-10.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE[3].QuenelleDC,etal.Efficacyofpritelivirandacyclovirinthetreatmentofherpessimplexvirusinfectionsinamousemodelofherpessimplexencephalitis.AntiviralRes.2018Jan;149:1-6.McePdfHeightCaution:Producthasnotbeenfullyvalidat